Overview

Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100

Status:
Recruiting
Trial end date:
2026-01-31
Target enrollment:
Participant gender:
Summary
To learn if the combination of dostarlimab and LB-100 can help to control ovarian clear cell carcinoma
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
GSK Pharma
Lixte
Treatments:
Dostarlimab
LB100